These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 31063995)

  • 1. Timing and Predictors of Recurrence of Dyspepsia Symptoms after Cessation of Acotiamide Therapy for Functional Dyspepsia: A Long-Term Observational Study.
    Shinozaki S; Osawa H; Sakamoto H; Hayashi Y; Kobayashi Y; Miura Y; Lefor AK; Yamamoto H
    Digestion; 2020; 101(4):382-390. PubMed ID: 31063995
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adherence to an acotiamide therapeutic regimen improves long-term outcomes in patients with functional dyspepsia.
    Shinozaki S; Osawa H; Sakamoto H; Hayashi Y; Miura Y; Lefor AK; Yamamoto H
    J Gastrointestin Liver Dis; 2017 Dec; 26(4):345-350. PubMed ID: 29253047
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of acotiamide on epigastric pain syndrome and postprandial distress syndrome in patients with functional dyspepsia.
    Shinozaki S; Osawa H; Sakamoto H; Hayashi Y; Kawarai Lefor A; Yamamoto H
    J Med Invest; 2016; 63(3-4):230-5. PubMed ID: 27644564
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term safety and efficacy of acotiamide in functional dyspepsia (postprandial distress syndrome)-results from the European phase 3 open-label safety trial.
    Tack J; Pokrotnieks J; Urbonas G; Banciu C; Yakusevich V; Bunganic I; Törnblom H; Kleban Y; Eavis P; Tsuchikawa M; Miyagawa T
    Neurogastroenterol Motil; 2018 Jun; 30(6):e13284. PubMed ID: 29315999
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-World, Non-Interventional, Observational Study to Evaluate Effectiveness and Tolerability of Acotiamide Hydrochloride Hydrate in Treatment of Functional Dyspepsia.
    Porika SK; Veligandla KC; Muni SK; Acharya S; Mehta SC; Sharma AD
    Adv Ther; 2018 Nov; 35(11):1884-1893. PubMed ID: 30350248
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emerging treatments in neurogastroenterology: Acotiamade, a novel treatment option for functional dyspepsia.
    Matsushita M; Masaoka T; Suzuki H
    Neurogastroenterol Motil; 2016 May; 28(5):631-8. PubMed ID: 26730749
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improvement of meal-related symptoms and epigastric pain in patients with functional dyspepsia treated with acotiamide was associated with acylated ghrelin levels in Japan.
    Yamawaki H; Futagami S; Kawagoe T; Maruki Y; Hashimoto S; Nagoya H; Sato H; Kodaka Y; Gudis K; Akamizu T; Sakamoto C; Iwakiri K
    Neurogastroenterol Motil; 2016 Jul; 28(7):1037-47. PubMed ID: 26920949
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of acotiamide on functional dyspepsia patients with heartburn who failed proton pump inhibitor treatment in Japanese patients: A randomized, double-blind, placebo-controlled crossover study.
    Funaki Y; Ogasawara N; Kawamura Y; Yoshimine T; Tamura Y; Izawa S; Ebi M; Sasaki M; Kasugai K
    Neurogastroenterol Motil; 2020 Feb; 32(2):e13749. PubMed ID: 31612597
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Randomized, Double-Blind, Pilot Study of the Effect of Famotidine on Acotiamide Treatment for Functional Dyspepsia.
    Hojo M; Nagahara A; Asaoka D; Takeda T; Izumi K; Matsumoto K; Ueyama H; Shimada Y; Matsumoto K; Nojiri S; Watanabe S
    Digestion; 2017; 96(1):5-12. PubMed ID: 28605740
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A double-blind placebo controlled study of acotiamide hydrochloride for efficacy on gastrointestinal motility of patients with functional dyspepsia.
    Nakamura K; Tomita T; Oshima T; Asano H; Yamasaki T; Okugawa T; Kondo T; Kono T; Tozawa K; Ohda Y; Fukui H; Kazuhito F; Hirota S; Watari J; Miwa H
    J Gastroenterol; 2017 May; 52(5):602-610. PubMed ID: 27639387
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A placebo-controlled trial of acotiamide for meal-related symptoms of functional dyspepsia.
    Matsueda K; Hongo M; Tack J; Saito Y; Kato H
    Gut; 2012 Jun; 61(6):821-8. PubMed ID: 22157329
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A long-term study of acotiamide in patients with functional dyspepsia: results from an open-label phase III trial in Japan on efficacy, safety and pattern of administration.
    Matsueda K; Hongo M; Ushijima S; Akiho H
    Digestion; 2011; 84(4):261-8. PubMed ID: 21934307
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical trial: dose-dependent therapeutic efficacy of acotiamide hydrochloride (Z-338) in patients with functional dyspepsia - 100 mg t.i.d. is an optimal dosage.
    Matsueda K; Hongo M; Tack J; Aoki H; Saito Y; Kato H
    Neurogastroenterol Motil; 2010 Jun; 22(6):618-e173. PubMed ID: 20059698
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic efficacy of acotiamide in patients with functional dyspepsia based on enhanced postprandial gastric accommodation and emptying: randomized controlled study evaluation by real-time ultrasonography.
    Kusunoki H; Haruma K; Manabe N; Imamura H; Kamada T; Shiotani A; Hata J; Sugioka H; Saito Y; Kato H; Tack J
    Neurogastroenterol Motil; 2012 Jun; 24(6):540-5, e250-1. PubMed ID: 22385472
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acotiamide, a novel gastroprokinetic for the treatment of patients with functional dyspepsia: postprandial distress syndrome.
    Altan E; Masaoka T; Farré R; Tack J
    Expert Rev Gastroenterol Hepatol; 2012 Sep; 6(5):533-44. PubMed ID: 23061703
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A dose-ranging, placebo-controlled, pilot trial of Acotiamide in patients with functional dyspepsia.
    Tack J; Masclee A; Heading R; Berstad A; Piessevaux H; Popiela T; Vandenberghe A; Kato H
    Neurogastroenterol Motil; 2009 Mar; 21(3):272-80. PubMed ID: 19254354
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapy of gastroesophageal reflux disease and functional dyspepsia overlaps with symptoms after usual-dose proton pump inhibitor: Acotiamide plus usual-dose proton pump inhibitor versus double-dose proton pump inhibitor.
    Takeuchi T; Takahashi Y; Kawaguchi S; Ota K; Harada S; Kojima Y; Sakamoto H; Kuramoto T; Kojima K; Sanomura M; Hoshimoto M; Higashino T; Itabashi T; Takada K; Sakaguchi M; Tominaga K; Kusano M; Higuchi K
    J Gastroenterol Hepatol; 2018 Mar; 33(3):623-630. PubMed ID: 28865098
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acotiamide: first global approval.
    Nowlan ML; Scott LJ
    Drugs; 2013 Aug; 73(12):1377-83. PubMed ID: 23881665
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acotiamide (Z-338, YM443), a new drug for the treatment of functional dyspepsia.
    Tack J; Janssen P
    Expert Opin Investig Drugs; 2011 May; 20(5):701-12. PubMed ID: 21417958
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of acotiamide in combination with esomeprazole for functional dyspepsia refractory to proton-pump inhibitor monotherapy.
    Mayanagi S; Kishino M; Kitagawa Y; Sunamura M
    Tohoku J Exp Med; 2014 Nov; 234(3):237-40. PubMed ID: 25382232
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.